3
Announcements
Trials
Browse
Landscape
Status
Completed
2
Terminated
1
Sponsor Class
OTHER
5
INDUSTRY
3
Study Type
Observational
3
Sponsor
Cancer Type
Gynecologic
5
NET
4
Endocrine
4
Thoracic
3
Genitourinary
3
Tumor-Agnostic
1
Myeloid
1
CNS
1
Conditions
Prostatic Neoplasms
2
Neoplastic Cells, Circulating
1
Carcinoma, Renal Cell
1
Interventions
pembrolizumab
164
Prednisone
129
enzalutamide
125
Docetaxel
122
Abiraterone Acetate
94
Nivolumab
92
Gemcitabine
71
Sunitinib
67
atezolizumab
49
Leuprolide
49
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
48
abiraterone
48
Cisplatin
48
Sorafenib
39
radium Ra 223 dichloride
38
Ipilimumab
38
darolutamide
37
apalutamide
37
Carboplatin
37
Prednisolone
33
Everolimus
33
Axitinib
32
avelumab
31
pazopanib
30
cabozantinib
30
Bevacizumab
30
Paclitaxel
29
enfortumab vedotin
28
bicalutamide
28
Cyclophosphamide
26
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
INDUSTRY
×
Data Collection
×
Genitourinary
×
Clear all
NCT03516110
2026-01-23
PRISME
Ipsen
Completed
831 enrolled
NCT05437679
2023-09-05
CHARTER
Angle plc
Terminated
9 enrolled
NCT03419572
2022-08-15
CASSIOPE
Ipsen
Completed
689 enrolled